These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22471728)

  • 1. The impact of sirolimus on sex hormones in male adolescent kidney recipients.
    González D; Álvarez-García O; Santos F
    Pediatr Transplant; 2012 Jun; 16(4):310-1. PubMed ID: 22471728
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of sirolimus on sex hormones in male adolescent kidney recipients.
    Cavanaugh TM; Schoenemen H; Goebel J
    Pediatr Transplant; 2012 May; 16(3):280-5. PubMed ID: 22372519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
    Teutonico A; Schena PF; Di Paolo S
    J Am Soc Nephrol; 2005 Oct; 16(10):3128-35. PubMed ID: 16107580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of sirolimus on sex hormone levels of male renal transplant recipients.
    Lee S; Coco M; Greenstein SM; Schechner RS; Tellis VA; Glicklich DG
    Clin Transplant; 2005 Apr; 19(2):162-7. PubMed ID: 15740550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal.
    Heilman RL; Younan K; Wadei HM; Mai ML; Reddy KS; Chakkera HA; Gonwa TA
    Transplantation; 2011 Oct; 92(7):767-73. PubMed ID: 21775930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin enhances lifespan: at last, an advantage for transplant recipients?
    Geissler EK
    Nephrol Dial Transplant; 2009 Dec; 24(12):3623-5. PubMed ID: 19773418
    [No Abstract]   [Full Text] [Related]  

  • 7. Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients.
    Baldan N; Rigotti P; Furian L; Margani G; Ekser B; Frison L; De Martin S; Palatini P
    Pharmacol Res; 2006 Sep; 54(3):181-5. PubMed ID: 16750634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of pre-conversion glomerular filtration rate in predicting long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients.
    Raza Z; Waheed A; Rizvi S; Boehmer JP
    J Heart Lung Transplant; 2011 Nov; 30(11):1301-2; discussion 1302. PubMed ID: 21816626
    [No Abstract]   [Full Text] [Related]  

  • 9. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil versus sirolimus as an adjunct to calcineurin inhibition after renal transplantation.
    Pavlakis M
    Nat Clin Pract Nephrol; 2006 Oct; 2(10):558-9. PubMed ID: 17003833
    [No Abstract]   [Full Text] [Related]  

  • 11. Sirolimus protective effects on bone: the need to be demonstrated.
    Luo LM; Wang LL
    Nephrol Dial Transplant; 2012 Jun; 27(6):2602-3. PubMed ID: 22323528
    [No Abstract]   [Full Text] [Related]  

  • 12. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
    Berthier CC; Wahl PR; Le Hir M; Marti HP; Wagner U; Rehrauer H; Wüthrich RP; Serra AL
    Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor.
    Durrbach A; Rostaing L; Tricot L; Ouali N; Wolf P; Pouteil-Noble C; Kessler M; Viron B; Thervet E
    Transplantation; 2008 Feb; 85(3):486-90. PubMed ID: 18301342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus: continuing the evolution of transplant immunosuppression.
    Ingle GR; Sievers TM; Holt CD
    Ann Pharmacother; 2000 Sep; 34(9):1044-55. PubMed ID: 10981252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sex hormones].
    Arai T
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():160-4. PubMed ID: 15250287
    [No Abstract]   [Full Text] [Related]  

  • 16. Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation.
    Constantinescu AR; Liang M; Laskow DA
    Am J Kidney Dis; 2002 Aug; 40(2):407-10. PubMed ID: 12148116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial function of sirolimus maintenance regimen in renal transplant recipients.
    Maamoun H; Esmail E; Soliman A
    Transplant Proc; 2011 Jun; 43(5):1616-8. PubMed ID: 21693243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
    Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
    Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrarenal vascular resistance parameters in kidney transplant patients receiving calcineurin inhibitor-based or sirolimus-based regimens.
    Lee PC; Lee CY; Hu RH; Lo C; Tsai MK; Lee PH
    Nephrol Dial Transplant; 2010 May; 25(5):1675-80. PubMed ID: 20042398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.